Jump to:
Lunglife Ai, INC Fundamentals
| Company Name | Lunglife Ai, INC | Last Updated | 2024-05-10 |
|---|
| Industry | Diagnostics & Research | Sector | Healthcare |
|---|
| Shares in Issue | 30.659 m | Market Cap | £7.97 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -$0.21 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.0363 | Debt Equity Ratio | 0.0143 |
|---|
| Asset Equity Ratio | 1.2033 | Cash Equity Ratio | 0.3574 |
|---|
| Quick Ratio | 2.0768 | Current Ratio | 2.28 |
|---|
| Price To Book Value | 1.2617 | ROCE | 0 |
|---|
Lunglife Ai, INC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Lunglife Ai, INC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|
| Tangible Assets | $389,000.00 | $566,000.00 | $766,000.00 |
| Intangible Assets | $5.82 m | $5.82 m | $5.82 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | $6.22 m | $6.40 m | $6.60 m |
| Stocks | 0 | 0 | 0 |
| Debtors | $175,000.00 | $155,000.00 | $741,000.00 |
| Cash & Equivalents | $2.83 m | $8.01 m | $14.63 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $9.52 m | $15.02 m | $21.97 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|
| Creditors within 1 year | $1.45 m | $1.48 m | $1.19 m |
| Creditors after 1 year | $163,000.00 | $396,000.00 | $651,000.00 |
| Other Liabilities | 0 | 0 | $174,000.00 |
| Total Liabilities | $1.61 m | $1.88 m | $1.84 m |
| Net assets | $7.91 m | $13.14 m | $20.13 m |
| Equity | 2023 | 2022 | 2021 |
|---|
| Called up share capital | $3,000.00 | $3,000.00 | $3,000.00 |
| Share Premium | $91.27 m | $91.27 m | $91.26 m |
| Profit / Loss | -$5.41 m | -$7.60 m | -$7.43 m |
| Other Equity | $7.91 m | $13.14 m | $20.13 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | $7.91 m | $13.14 m | $20.13 m |
| Ratios | 2023 | 2022 | 2021 |
|---|
| Debt Ratio | $0.01 | $0.03 | $0.03 |
| Debt-to-Equity | $0.01 | $0.03 | $0.03 |
| Assets / Equity | 1.2033 | 1.2033 | 1.2033 |
| Cash / Equity | 0.3574 | 0.3574 | 0.3574 |
| EPS | -$0.21 | -$0.30 | -$0.39 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|
| Cash from operating activities | -$5.02 m | -$5.84 m | -$7.54 m |
| Cashflow before financing | -$5.32 m | -$6.10 m | $16.30 m |
| Increase in Cash | -$364,000.00 | -$6.13 m | $9.09 m |
| Income | 2023 | 2022 | 2021 |
|---|
| Turnover | $46,000.00 | $24,000.00 | $195,000.00 |
| Cost of sales | 0 | 0 | $96,000.00 |
| Gross Profit | $46,000.00 | $24,000.00 | $99,000.00 |
| Operating Profit | -$5.63 m | -$7.74 m | -$7.23 m |
| Pre-Tax profit | -$5.41 m | -$7.60 m | -$7.43 m |
Lunglife Ai, INC Company Background
| Sector | Healthcare |
|---|
| Activities | LungLife AI Inc is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence. Its LungLB Test is a blood-based tool developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer. |
|---|
| Latest Interim Date | 8 Aug 2023 |
|---|
| Latest Fiscal Year End Date | 4 Apr 2024 |
|---|
Lunglife Ai, INC Directors
| Appointed | Name | Position |
|---|
| 2024-04-25 | Mr. Andrew Norman Boteler | Non-Executive Director,Senior Independent Non-Executive Director |
| 2023-04-10 | Mr. James Renwick McCullough | Non-Executive Director |
| 2023-04-10 | Ms. Sara Jane Barrington | Non-Executive Director |
| 2024-04-25 | Dr. Paul Carmelo Pagano | Executive Director,Chief Executive Officer |
| 2024-04-25 | Mr. Gordon Roy Davis | Non-Executive Director,Chairman |
| 2024-04-25 | Mr. David Mark Anderson | Executive Director,Chief Financial Officer and Company Secretary |
Lunglife Ai, INC Contact Details
Lunglife Ai, INC Advisors
